New shot tested to shrink stubborn nasal polyps
NCT ID NCT06454240
Summary
This study is testing whether a new injectable drug called lunsekimig can safely reduce nasal polyps and improve symptoms in adults with chronic sinusitis. Participants will receive either the drug or a placebo for 24 weeks to see which is more effective. The goal is to find a better treatment for people whose symptoms are not controlled by standard nasal sprays.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Research Institute - Odgen- Site Number : 8400022
Ogden, Utah, 84405, United States
-
Alamo ENT Associates Site Number : 8400001
San Antonio, Texas, 78258, United States
-
Allergy & Rheumatology- Site Number : 8400005
La Jolla, California, 92037, United States
-
Berkson Medical - McKinney- Site Number : 8400014
McKinney, Texas, 75070, United States
-
Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400008
Norfolk, Virginia, 23510, United States
-
Emory University Hospital Midtown- Site Number : 8400012
Atlanta, Georgia, 30308, United States
-
Essential Medical Research- Site Number : 8400020
Tulsa, Oklahoma, 74137, United States
-
Gary Gross Pharmaceutical Research & Consulting, Inc. Site Number : 8400004
Dallas, Texas, 75231, United States
-
Harvard Medical School - Brigham and Women's Hospital Site Number : 8400016
Boston, Massachusetts, 02115, United States
-
Investigational Site Number : 0320001
Buenos Aires, 1121, Argentina
-
Investigational Site Number : 0320002
Rosario, Santa Fe Province, 2000, Argentina
-
Investigational Site Number : 0320003
Mendoza, 5500, Argentina
-
Investigational Site Number : 0560001
Leuven, 3000, Belgium
-
Investigational Site Number : 0560002
Ghent, 9000, Belgium
-
Investigational Site Number : 1000001
Sofia, 1612, Bulgaria
-
Investigational Site Number : 6160001
Warsaw, Masovian Voivodeship, 00-909, Poland
-
Investigational Site Number : 6160002
Krakow, Lesser Poland Voivodeship, 31-033, Poland
-
Investigational Site Number : 6160003
Katowice, Silesian Voivodeship, 40-611, Poland
-
Investigational Site Number : 6160004
Poznan, 60-693, Poland
-
Investigational Site Number : 6160005
Warsaw, Masovian Voivodeship, 02-507, Poland
-
Investigational Site Number : 6160007
Wroclaw, 53-034, Poland
-
Investigational Site Number : 8260001
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
Investigational Site Number : 8260003
Manchester, M13 9WL, United Kingdom
-
Investigational Site Number : 8260004
Gloucester, Gloucestershire, GL1 3NN, United Kingdom
-
James A Haley Veterans' Hospital- Site Number : 8400015
Tampa, Florida, 33612, United States
-
McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8400017
Bellaire, Texas, 77401, United States
-
Sacramento Ear Nose & Throat - Roseville- Site Number : 8400003
Roseville, California, 95661, United States
-
Senta Clinic- Site Number : 8400025
San Diego, California, 92018, United States
-
The Allergy Group - Asthma & Allergy Boise- Site Number : 8400002
Boise, Idaho, 83706, United States
Conditions
Explore the condition pages connected to this study.